Ipsen: targets raised for 2024
(CercleFinance.com) - On the back of a good Q3 performance, Ipsen has again raised its targets for 2024, now targeting an operating margin of over 31% of sales (instead of 'over 30%').
Similarly, the pharmaceutical company now anticipates sales growth at constant exchange rates (CER) of over 8% (instead of 'over 7%'), but with an additional unfavorable currency impact of around 1.5%.
For the first nine months of the year, Ipsen posted sales of just under E2.5bn, up 8.1% as reported and up 9.2% at constant exchange rates (including +5.8% in oncology, +11.8% in neuroscience and +71.3% in rare diseases).
It highlights significant performances by Dysport, Cabomety and Bylvay, solid sales by Somatuline, and a growing contribution from the launches of Iqirvo in PBC and Onivyde in metastatic pancreatic ductal adenocarcinoma.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Similarly, the pharmaceutical company now anticipates sales growth at constant exchange rates (CER) of over 8% (instead of 'over 7%'), but with an additional unfavorable currency impact of around 1.5%.
For the first nine months of the year, Ipsen posted sales of just under E2.5bn, up 8.1% as reported and up 9.2% at constant exchange rates (including +5.8% in oncology, +11.8% in neuroscience and +71.3% in rare diseases).
It highlights significant performances by Dysport, Cabomety and Bylvay, solid sales by Somatuline, and a growing contribution from the launches of Iqirvo in PBC and Onivyde in metastatic pancreatic ductal adenocarcinoma.
Copyright (c) 2024 CercleFinance.com. All rights reserved.